Search work for a pharmaceutical company is not limited by ideas; it is limited by what may be said. Promotional material about a prescription product is regulated, review by medical, legal and regulatory reviewers is not optional, and a page published outside that process is a compliance incident rather than a ranking experiment.
Promotional and non-promotional are different perimeters
Promotional material about a prescription product carries requirements about balance, risk information and the indication it may discuss, and the rules are explicit that advertising must not be false or misleading and must present risk alongside benefit. Disease awareness and scientific information sit in a different space with different constraints. The first job of any programme is knowing which perimeter each proposed page sits in, because the writing, the review and the timeline all follow from that.
The review process is the schedule
Copy passes through medical, legal and regulatory review, and that cycle is measured in weeks rather than days. A publishing plan that assumes a weekly cadence will produce a queue of unapproved drafts. Build the calendar backwards from the review committee's meeting schedule, batch submissions, and agree in advance which classes of change can be made without a fresh review.
Unbranded and patient-facing content is where the search volume is
Most of the searching is done by patients and carers asking about a condition rather than a product, and disease-state material can serve that without becoming product promotion. It still needs review, accuracy and a clear route to a clinician rather than to a purchase. This is the honest place for the volume, and it is where an agency with regulatory experience earns its premium.
Choosing the supplier
Ask which review processes they have worked inside, how long their approvals took, and for an example of copy that came back rejected and what they changed. An agency that has never had a submission rejected has never submitted one. Ask who on their side is accountable for a compliance failure, and read the indemnity clause before signing.
Questions people ask about pharmaceutical seo company
Can we run paid search on a branded drug term?
Sometimes, with heavy constraints and platform certification requirements in some markets, and the same balance and risk rules apply to the ad. Confirm both the regulatory and platform positions before budgeting.
Does disease awareness content need review?
Yes. It is still material published by the company about a condition it sells into, and it carries accuracy and claim obligations of its own.
How long should we expect approvals to take?
Weeks rather than days in most organisations, and longer for anything novel. Plan the cadence around the committee, not around the agency's capacity.
Can an agency without pharma experience do this work?
They can write, but they will not anticipate what review will reject, which is most of the cost. The premium buys fewer rejected submissions, not better prose.